Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Profusa Inc (PFSA)

Profusa Inc (PFSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,470
  • Shares Outstanding, K 1,229
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,710 K
  • EBIT $ -24 M
  • EBITDA $ -24 M
  • 60-Month Beta -0.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.80 +4.44%
on 02/17/26
9.08 -79.28%
on 01/23/26
-5.81 (-75.54%)
since 01/16/26
3-Month
1.80 +4.44%
on 02/17/26
15.17 -87.60%
on 12/04/25
-11.25 (-85.68%)
since 11/17/25

Most Recent Stories

More News
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new...

PFSA : 1.88 (-6.47%)
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new...

PFSA : 1.88 (-6.47%)
Profusa Announces 1-for-75 Reverse Stock Split

BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology...

PFSA : 1.88 (-6.47%)
Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026

Study conducted at US sites evaluates Lumee TM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”)...

PFSA : 1.88 (-6.47%)
Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue

Research-use-only offerings are commercially available, enabling immediate product and service revenue generation Targets the global CRO market of $47.9 billion in 2025 and growing at 7% CAGR ...

PFSA : 1.88 (-6.47%)
Profusa Adds Leading Greek Vascular Surgeon to Customer Base

Dr. Theodosios Bisdas is a renowned vascular surgeon and Head of Clinic of Vascular Surgery at the Athens Medical Center BERKELEY, Calif, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa”...

PFSA : 1.88 (-6.47%)
Profusa Bolsters European Commercial Network with New French Distributor, MedSell

MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now...

PFSA : 1.88 (-6.47%)
Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35

New note provides greater repayment flexibility and less dilution with elimination of mandatory amortization payments, increased conversion floor price to $0.35, and expanded mandatory ELOC payments from...

PFSA : 1.88 (-6.47%)
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025

Data from FDA-advised study demonstrates Lumee™ Oxygen tissue monitoring is a safe and effective long-term method in PAD patients and will support potential FDA submission; strongly correlates with transcutaneous...

PFSA : 1.88 (-6.47%)
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026

Study conducted at US sites evaluates Lumee TM in peripheral artery disease (PAD) patients BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”)...

PFSA : 1.88 (-6.47%)

Business Summary

Profusa Inc. is a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry. Profusa Inc., formerly known as NorthView Acquisition Corp., is based in BERKELEY, Calif.

See More

Key Turning Points

3rd Resistance Point 2.12
2nd Resistance Point 2.04
1st Resistance Point 1.96
Last Price 1.88
1st Support Level 1.80
2nd Support Level 1.72
3rd Support Level 1.64

See More

52-Week High 180.00
Fibonacci 61.8% 111.93
Fibonacci 50% 90.90
Fibonacci 38.2% 69.87
Last Price 1.88
52-Week Low 1.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar